Mode
Text Size
Log in / Sign up
N/A N=81 Randomized Double-blind Treatment

A Smartphone-Assisted Brief Behavioral Intervention for Pregnant Women With Depression

Perinatal Depression

Enrolled (actual)
81
Serious AEs
0.0%
Results posted
Jan 2022
Primary outcome: Primary: Change in Maternal Prenatal Depression at Baseline, Midpoint, and Posttreatment (8 Weeks) — 17.3; 16.8; 12.5; 12.1 score on EPDS — p=0.757

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Motherly 1.0 (Behavioral); Brief Psychotherapy (Behavioral); Educational app (Behavioral)
Age
Pediatric, Adult · 16+ yrs
Sex
Female
Sponsor
University of Sao Paulo
Primary completion
Nov 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Maternal Prenatal Depression at Baseline, Midpoint, and Posttreatment (8 Weeks)
17.3; 16.8; 12.5; 12.1; 11.1; 10.8 0.757
SECONDARY
Change in Maternal Prenatal Anxiety From Baseline to Posttreatment (8 Weeks)
14.0; 13.5; 11.1; 10.9; 9.8; 9.7 0.910
SECONDARY
Change in Maternal Prenatal Quality of Life From Baseline to Posttreatment (8 Weeks)
SECONDARY
Change in Maternal Prenatal Psychological Well-Being From Baseline to Posttreatment (8 Weeks).
149.7; 140.4; 157.6; 153.0 0.442
SECONDARY
Change in Maternal Physical Activity Levels From Baseline to Posttreatment (8 Weeks).
1626.0; 2160.1; 2770.0; 1540.1 0.223
SECONDARY
Change in Maternal Prenatal Perceived Stress From Baseline to Posttreatment (8 Weeks).
26.5; 26.6; 25.6; 25.0; 23.9; 22.9 0.540
SECONDARY
Change in Maternal Prenatal Depression Severity From Baseline to Posttreatment (8 Weeks).
63; 73; 80; 80 0.901
SECONDARY
Change in Maternal Prenatal Sleep Quality From Baseline to Posttreatment (8 Weeks).
4.6; 4.6; 5.6; 5.0; 5.6; 5.4 0.748
SECONDARY
Infant Developmental Milestones at 2 Months of Age.
SECONDARY
Infant Social/Emotional Problems at 2 Months of Age.
SECONDARY
Change in Maternal Prenatal Depression From Baseline to Follow-up.
SECONDARY
Change in Maternal Prenatal Anxiety From Baseline to to Follow-up.
SECONDARY
Change in Maternal Prenatal Quality of Life From Baseline to to Follow-up.
SECONDARY
Change in Maternal Prenatal Psychological Well-Being From Baseline to Follow-up.
SECONDARY
Change in Maternal Prenatal Perceived Stress From Baseline to Follow-up.
SECONDARY
Change in Maternal Prenatal Depression Severity From Baseline to Follow-up.
SECONDARY
Change in Maternal Prenatal Sleep Quality From Baseline to Follow-up.

Summary

Investigators developed Motherly 1.0, a smartphone app designed to treat and promote maternal mental health. A 2-arm parallel-randomized controlled clinical trial (RCT) will be conducted to test the efficacy of Motherly in conjunction with brief cognitive-behavioral therapy. 70 pregnant women between 16-40 years old will be recruited. Since all interventions will be conducted online, participants will be recruited from any Brazilian state or municipality. Participants will be randomly assigned to either receive intervention via app consisting of behavioral activation and psychoeducation to promote changes in sleep, nutrition, and physical activity habits, as well as to engage in prenatal care, breastfeeding, and social support, and to stimulate child development, in addition to brief cognitive-behavioral therapy (CBT) (n=35); or to a comparison group receiving an psychoeducational app (active control) with psychoeducational content about gestation, maternal health and mental health, and child development in addition to brief CBT (n=35). Duration of treatment will be eight weeks, during which participants in both groups will be assessed at the beginning (baseline; T0), weeks 3-4 (midpoint; T1), and week 8 (endpoint; T2) in order to evaluate treatment effects. A follow-up postnatal assessment will also be conducted when the child is three months of age (T3).

Eligibility Criteria

Inclusion Criteria

  • women aged between 16-40 years;
  • having a score of >7 on the Edinburgh Postnatal Depression Scale (EPDS);
  • gestational age between 17-26 weeks;
  • being literate;
  • owning a functional smartphone with Android for personal use.

Exclusion Criteria

  • pregnancies classified as being at risk, fetal malformation, or congenital disease;
  • visual, auditory or intellectual disabilities, or chronic diseases associated with fetal development alterations;
  • severe and/or chronic mental disorder (e.g., schizophrenia, bipolar disorder, etc).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04495166). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search